Adira is pleased to announce uniQure as a sponsor

uniQure is delivering on the promise of gene therapy—single treatments with potentially transformative results.

First gene therapy for Huntington’s

We are utilizing our technology to advance a pipeline of gene therapies to treat patients with neurodegenerative diseases, and other severe genetic diseases. We are currently conducting a phase 1/2 trial in Huntington’s disease, the first gene therapy ever in the clinic for HD.

The next program in the pipeline is for spinocerebellar ataxia (SCA3) and we hope to file an application to the United States Food and Drug Administration this year to get approval to begin an early phase clinical trial.

We are happy to support Adira in its efforts to bring together communities across the neurodegenerative disease spectrum, in particular around education on emerging therapies such as gene therapy.

UniQure Logo

We are happy to support Adira in its efforts to bring together communities across the neurodegenerative disease spectrum, in particular around education on emerging therapies such as gene therapy.